As of 8:10 PM 05/1/15 All times are local (Market data is delayed by at least 15 minutes).
lpath inc-class a (LPTN) Key Developments
Lpath Inc. - Shareholder/Analyst Call
Mar 23 15
To update investors on the progress of Lpath's programs
Lpath Inc. Submits Investigational New Drug Application for Lpathomab for Neuropathic Pain
Feb 2 15
Lpath Inc. announced that it has submitted an Investigational New Drug (IND) application to the United States Food and Drug Administration (FDA) to conduct a Phase 1 study of Lpathomab™ for the treatment of neuropathic pain. The primary objective of the study is to evaluate the safety and tolerability of Lpathomab in subjects that are experiencing neuropathic pain. Lpath plans to begin enrolling patients once the FDA's IND review period is complete and the study has been approved by the trial sites' investigational review boards. Lpathomab is an internally discovered, first-in-class antibody targeting Lysophosphatidic Acid, or LPA, a bioactive lipid that has been characterized in the scientific literature as playing a key role in nerve injury and neuropathic pain. Lpath's preclinical studies showed strong in vivo results with Lpathomab in several different pain models, which suggest that LPA may be an attractive target across a variety of chronic pain conditions, including diabetic peripheral neuropathy, post-herpetic neuralgia, chemotherapy-induced neuropathic pain and pain associated with lumbosacral radiculopathy.
Lpath Inc. - Special Call
Dec 2 14
To update on the progress of the Nexus trial as well as other programs
Lpath Announces Executive Changes
Nov 4 14
Lpath Inc. announced that Scott Pancoast has resigned as president, chief executive officer and a member of the board of directors, effective from November 3, 2014. The board of directors has appointed biotechnology consultant Michael Lack as the company's interim chief executive officer while the board conducts a search for a new CEO. Mr. Pancoast served as the president and CEO of Lpath since March 2005 and as a director of Lpath since 1998. Mr. Lack currently serves as a member of the board of directors of Immunomic Therapeutics Inc.
Lpath Mulls Acquisitions
Sep 19 14
Lpath Inc. (NasdaqCM:LPTN) is seeking acquisitions. Lpath Inc. has completed a follow-on equity offering in the amount of $12.53 million. Lpath said that it plans to raise funds via direct offering and plans to use part of proceeds for acquisitions too. Lpath said, "Lpath may also use a portion of the net proceeds to invest in or acquire businesses or technologies that it believes are complementary to its own, although it has no current plans, commitments or agreements with respect to any acquisitions as of the date hereof."
Sponsored Financial Commentaries